Article metrics
PDF
Other content recommended for you
- Phase I oncology trials: why the therapeutic misconception will not go away
- Assessing risk/benefit for trials using preclinical evidence: a proposal
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
- Subjects’ views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study
- The Applicability of Lean and Six Sigma Techniques to Clinical and Translational Research
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- Long term effects of locomotor training in spinal humans
- Is animal research sufficiently evidence based to be a cornerstone of biomedical research?
- The rights and wrongs of intentional exposure research: contextualising the Guatemala STD inoculation study
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)